PPPatricia Possler

Patricia Possler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Possler has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study

    by Hannah Labinsky, Amelie Wuest, Patricia Possler, Tobias Heusinger, Maxime le Maire, Anna Fleischer, Karsten Sebastian Luetkens, Michael Gernert, Ottar Gadeholt, Robert Leppich, et al.

    Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. Objective: This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. Methods: This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). Results: The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. Conclusions: Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.

  • Open Access

    Assessment of App Quality, User Experience, and Willingness to Recommend a Digital Therapeutic for Patients With Axial Spondyloarthritis: Subanalysis of a 12-Week Pretest-Posttest Intervention Study (Preprint)

    by Hannah Labinsky, Amelie Wuest, Patricia Possler, Tobias Heusinger, Maxime le Maire, Anna Fleischer, Karsten Sebastian Luetkens, Michael Gernert, Ottar Gadeholt, Robert Leppich, et al.

    BACKGROUND Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the axial skeleton that requires regular physical exercise in addition to pharmacotherapy. However, a significant proportion of patients do not exercise frequently enough. Axia is a digital therapeutic (DTx) that offers a solution by providing a disease-specific and patient-tailored home-based exercise program for patients with axSpA. The app combines structured exercise with patient education and disease management features and incorporates gamification and behavioral conditioning to promote user engagement. However, it has remained unclear how Axia is perceived and evaluated by patients. OBJECTIVE This study aimed to describe app quality, user experience, and willingness to recommend the app to others after 12 weeks of use by applying standardized questionnaires. METHODS This single-center study was conducted at an outpatient tertiary clinic. After 12 weeks of ad libitum app use, 27 participants with axSpA completed paper-based assessments of the user version of the Mobile App Rating Scale (uMARS; range 1-5) and the net promoter score (NPS; range −100% to +100%). RESULTS The mean overall uMARS app quality score was 4.44 (SD 0.43). Functionality received the highest mean score (4.54, SD 0.53), whereas information received the lowest (4.34, SD 0.49). The mean NPS was 9.52 (SD 0.75), corresponding to an overall NPS of 93%. The uMARS overall quality score correlated strongly with the NPS (ρ=0.57; P=.002). Except for physical therapy at baseline, no other baseline characteristic or therapeutic effect correlated with either the uMARS or NPS. CONCLUSIONS Axia was perceived as a user-friendly DTx after 12 weeks of use. The findings support the acceptability of disease-specific DTx for patients with axSpA and the potential integration of DTx into routine care.

  • Open Access

    The exercise-app Axia for axial spondyloarthritis enhances the home-based exercise frequency in axial spondyloarthritis patients – A cross-sectional survey

    by Patrick-Pascal Strunz, Maxime Le Maire, Tobias Heusinger, Juliana Klein, Hannah Labinsky, Anna Fleischer, Karsten Sebastian Luetkens, Patricia Possler, Michael Gernert, Robert Leppich, et al.

    Background: Patients with axial spondyloarthritis (axSpA) benefit from regular home-based exercise (HbE). In spite of recommendations, a relevant proportion of German axSpA patients does not adhere to recommended HbE practices. To enhance HbE care, we developed the novel digital therapeutic (DTx) “Axia” compliant with the European medical device regulation (MDR). Axia offers a modern app-based HbE solution with patient educative content and further integrated features. Objective: We aimed to assess Axia’s efficacy, attractiveness, and functionality through a survey among axSpA-patients involved in the first user tests. Methods: A mixed-method online questionnaire with 38 items was administered to 37 axSpA volunteers after using Axia. Numeric rating scales (NRS) and likelihood scales were primarily used. Results: HbE frequency significantly increased from a median of 1 day/week to 6 days/week (p < 0.001) by using Axia. Existing HbE practitioners also increased their frequency (median of 4 days/week before, 6 days/week with Axia, p < 0.05). Axia received a median rating of 5 out of 5 stars. On NRS scales, Axia scored a median of 9 for intuitiveness and design, and a median of 8 for entertainment. 64.9% reported improved range of motion, 43.2% reported reduced pain, and 93.6% enhanced disease-specific knowledge. All users recommended Axia to other patients. Conclusion: Axia increases axSpA patients HbE frequency, possibly due to its good intuitiveness and design, leading to reduction in pain and subjective improvement of range of motion. This warrants further investigation in large randomized controlled interventional trials to establish its efficacy conclusively and patients adherence to HbE.